Skip to main content
SpineGuard logo

SpineGuard — Investor Relations & Filings

Ticker · ALSGD ISIN · FR0011464452 LEI · 969500Z4BRXQX6CSL565 PA Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2022-01-31 Regulatory Filings
Country FR France
Listing PA ALSGD

About SpineGuard

https://www.spineguard.com/

SpineGuard is a medical technology company that develops and markets the proprietary Dynamic Surgical Guidance (DSG) technology. DSG is a radiation-free, real-time sensing platform designed to make spine surgery safer. The technology is embedded in the company's PediGuard family of smart drilling instruments, which assist surgeons in the accurate placement of skeletal implants, particularly pedicle screws. By differentiating tissue types at the instrument's tip, the devices provide audible and visual feedback to help anticipate potential breaches of the vertebral wall, thereby enhancing procedural safety and accuracy. SpineGuard's primary goal is to establish DSG as a standard of care for securing and streamlining skeletal implant placement.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 90% confidence The document is a press release dated January 31, 2022, announcing that SpineGuard has submitted its '510K' application to the US FDA for regulatory approval of its PediGuard device for use in anterior spinal surgery. The text details the significance of this regulatory filing for market expansion and mentions collaboration with another company. This type of announcement, detailing a significant regulatory submission or action that is not a full financial report (like 10-K or IR) or a general regulatory filing (RNS), best fits the category for updates on financing, capital structure, or significant operational/regulatory milestones that impact the business structure or future operations. However, none of the provided codes perfectly match a 'Regulatory Submission Announcement' for a medical device. Given the options, this is a significant corporate announcement regarding a key operational/regulatory milestone impacting future sales and market access. It is not an Earnings Release (ER), Interim Report (IR), or a standard Legal Proceeding Report (LTR). Since it is a specific announcement about a regulatory step (510K submission) that is crucial for market entry, and it is not a general regulatory filing (RNS) or a capital event (CAP), it is most closely related to a significant corporate update. In the context of the provided definitions, 'Regulatory Filings' (RNS) is often used as a catch-all for non-standard announcements, but this is a very specific type of announcement. Given the focus on regulatory approval for a product, and lacking a specific 'Regulatory Approval Filing' code, I will evaluate against the closest fit. It is not a financing event (CAP), nor a management change (MANG). It is a specific announcement about a regulatory process. If we must choose from the list, and recognizing that many regulatory submissions are announced via press release, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate general category for a non-financial, non-management, non-legal, non-dividend, non-shareholder meeting announcement concerning regulatory progress, especially when a more specific code is unavailable. However, let's re-examine the definitions. This is a press release announcing a regulatory submission. It is not a financial report, dividend, or management change. It is a corporate update. Since it is a press release announcing a specific regulatory step, 'RNS' (Regulatory Filings) serves as the best general fit for significant, non-standard corporate news announcements.
2022-01-31 French
Inside Information / Information on annual revenues
Earnings Release Classification · 98% confidence The document explicitly states it reports 'full-year 2021 revenue' and provides detailed quarterly and full-year revenue figures in a tabular format, comparing 2021 to 2020. This content is characteristic of an Earnings Release (ER), which provides initial financial results and highlights. Although it contains some forward-looking statements and cash position details, the primary focus is the announcement of the annual revenue performance. It is not a comprehensive Annual Report (10-K) or a formal Interim Report (IR), but rather the initial release of the period's financial performance summary. FY 2021
2022-01-26 English
Informations privilégiées / Information sur chiffre d’affaires annuel
Earnings Release Classification · 98% confidence The document is titled "SpineGuard annonce son chiffre d'affaires 2021" (SpineGuard announces its 2021 revenue) and provides a detailed breakdown of quarterly and annual revenue figures for the fiscal year ending December 31, 2021. It also includes commentary on business performance, cash position, and outlook for 2022. This content structure—announcing key financial results for a period—is characteristic of an Earnings Release (ER). Although it contains some forward-looking statements and operational details, the primary focus is the release of the annual financial performance figures, which distinguishes it from a comprehensive Annual Report (10-K) or a Management Discussion & Analysis (MDA). It is not a transcript (CT) or a formal audit report (AR). FY 2021
2022-01-26 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Transaction in Own Shares Classification · 95% confidence The document is titled "Bilan semestriel du contrat de liquidité contracté avec la société de bourse TSAF" (Semi-annual balance sheet of the liquidity contract concluded with the brokerage firm TSAF) and reports on the status and transactions of a liquidity contract as of 31/12/2021, comparing it to the previous semi-annual balance (30/06/2021). This document details the activity related to maintaining market liquidity for the company's shares, which is a specific type of financial arrangement. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR). It specifically details transactions and balances related to share trading under a contract, which strongly aligns with activities related to share capital management or specific regulatory disclosures concerning market making/liquidity provision. Given the options, this document reports on the status of a specific financial arrangement involving share transactions, which is closest in nature to a disclosure about capital structure or share activity, but most precisely, it is a periodic report on a specific financial contract. Since there is no direct category for 'Liquidity Contract Report', I must evaluate the closest fit. It details share transactions (buys/sells) and resulting share/cash balances. This is related to share activity, but the context is a contractual obligation, not a general buyback program (POS) or a general capital change (SHA). However, the core activity described is the execution of share transactions under a contract. In the context of financial reporting, reports detailing the activity of share repurchase/issuance programs often fall under POS (Transaction in Own Shares). While this is a liquidity contract, the data presented is the result of share transactions. Given the specific nature, and lack of a better fit, I will check if it relates to insider trading (DIRS) or capital changes (SHA/POS). It is a report on the activity of a liquidity provider, which involves buying and selling shares. This is most analogous to a report on share transactions, even if mandated by a specific contract. If we consider the closest fit among the provided codes, 'POS' (Transaction in Own Shares) covers share repurchase/issuance. Since the document details the net effect of buying and selling shares under the contract, it is the most relevant category describing the underlying activity, although the document itself is a 'Bilan Semestriel' (Semi-annual Balance). Given the options, and the focus on share transactions, POS is a plausible, though imperfect, fit. However, if this is a mandatory disclosure related to market operations rather than a voluntary buyback, 'RNS' (Regulatory Filings) might be safer. Since it is a structured, periodic report detailing specific financial activity (share transactions under contract), and not just a general announcement, I lean towards the category describing the activity. Let's re-evaluate. This is a report on a liquidity contract balance. This is often disclosed as part of ongoing obligations. It is not a standard financial statement. It is a specific disclosure. If it were a general announcement about the contract, RNS would fit. Since it contains detailed transaction tables, it is a report. Given the options, and the focus on share transactions, POS is the closest activity-based classification. I will assign a moderate confidence due to the ambiguity between a specific contract report and a general share transaction report. *Self-Correction/Refinement*: The document is a 'Bilan Semestriel' (Semi-annual Report) on a liquidity contract. This is a specific regulatory/contractual disclosure. It is not a standard 10-K, IR, or ER. It is a report detailing share transactions (A/V) and cash balances. This type of disclosure often falls under general regulatory announcements if a specific code isn't available. Since it is a detailed report, it is not RPA. It is not DIRS (insider trading). It is not SHA (general capital change). It is a report on share activity under a specific agreement. I will classify it as RNS (Regulatory Filings) as the fallback for specific, non-standard disclosures, as it doesn't perfectly match POS (which usually implies the company buying its own stock, not a third-party liquidity provider's activity on its behalf, although the effect is similar). Given the French context and the nature of liquidity contract reporting, RNS is the most appropriate catch-all for a specific, non-standard periodic report.
2022-01-18 French
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is titled "SpineGuard announces its 2022 financial calendar" and explicitly lists dates for the publication of various financial reports (Sales, Full-Year Results, First-Half Results, etc.) and the date for the Annual Shareholders Meeting. It also announces an upcoming investors webinar. Since the document's primary purpose is to announce the schedule for future report publications and a related investor event, it fits the definition of a Report Publication Announcement (RPA). It is not the report itself (like 10-K or IR), nor is it a transcript (CT) or a formal AGM material (AGM-R), but rather an announcement *about* those future events and publications.
2022-01-12 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is a press release dated January 12, 2022, announcing the company's financial calendar for 2022 (including dates for 2021 annual revenue, 2021 annual results, and the AGM) and the scheduling of an Investor Webinar on January 27, 2022. Since the document's primary purpose is to announce the *timing* and *details* of future reports (like the Annual Results on April 20th) and an investor event, it fits the definition of a Report Publication Announcement (RPA). It is not the full Annual Report (10-K), the Interim Report (IR), or the Earnings Release (ER) itself, but rather an announcement about them and an associated investor call.
2022-01-12 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.